Stryker Q4 net sales rise 11.4%, beat estimates
I'm PortAI, I can summarize articles.
Stryker's Q4 net sales rose 11.4%, surpassing analyst expectations, with adjusted EPS increasing by 11.5%. The company forecasts 2026 organic net sales growth of 8.0% to 9.5% and adjusted EPS between $14.90 and $15.10. Key growth drivers included a 17.5% increase in MEDSURG and NEUROTECHNOLOGY sales and an 8.4% rise in the ORTHOPAEDICS segment. The average analyst rating is "buy," with a median 12-month price target of $432.50, reflecting a potential 20.9% increase from its recent trading price of $357.83.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments